BioSpace News Archive

The company’s pipeline changes come as it weathered a nearly 30% decline in first-quarter revenues due to a slowdown in its COVID-19 business.

Many employers aren’t offering the high salaries employees had grown accustomed to in recent years, leaving workers to decide whether they should accept a pay cut.

Despite the Phase III failure, Travere and partner CSL Vifor will explore potential regulatory paths for sparsentan as a treatment for focal segmental glomerulosclerosis.

The regulatory decision marks a turning point in the RSV race in what’s expected to be a competitive space.

The amyloid plaque targeting therapy met primary endpoint and all secondary endpoints, which Lilly will use in its submission to the FDA this quarter.

Innate Pharma SA announced three abstracts including Innate’s product candidates have been accepted for the American Society for Clinical Oncology 2023 Annual Meeting, taking place June 2-6, 2023 in Chicago, IL. One abstract for SAR’579, currently developed by Sanofi, has been selected for oral presentation.

Genezen announced a poster presentation at the 26th Annual American Society for Gene and Cell Therapy Conference in Los Angeles in May – highlighting the results of its evaluation of novel technologies for lentiviral physical titer determination.

Lytix Biopharma AS is pleased to announce that Dr Øystein Rekdal, CEO in Lytix Biopharma, will give an oral presentation at the `Frontiers in Cancer Immunotherapy 2023' conference, which is taking place in New York, USA.

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing and manufacturing niche generic products, announced the appointment of Mark Pellegrino as its Chief Financial Officer, effective May 1, 2023.

NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2023.